Abzena expands management team appointing Campbell Bunce to the role of Chief Scientific Officer

Cambridge, UK and San Diego, USA, 28 March 2019 – Abzena, the leading global biologics target to GMP partner research organization, announced it has appointed Dr Campbell Bunce as Chief Scientific Officer (CSO).

Dr Campbell Bunce joined Abzena in November 2015 as SVP Scientific Operations and Cambridge UK site head. The newly created CSO role recognizes the strong innovation focus and depth of scientific expertise that customers expect from Abzena in biologic and Antibody Drug Conjugate design, discovery and development, as well as an expectation of seamless execution. Dr Bunce will maintain his Cambridge UK site head responsibilities in addition to this global role.

Campbell is a twenty-year veteran of the biotechnology industry. Throughout his career he has applied innovative solutions for the design , manufacture and clinical evaluation of novel products including vaccines, biologics and small molecules in multiple therapeutic areas. These include inflammation, cancer, infectious disease and addiction. Since joining Abzena, he has guided the expansion of its integrated capabilities across discovery, developability, protein engineering, cell line development, bioconjugation, analytics and bioassay services. His education includes a PhD from the University of Manchester, an undergraduate degree from the University of Glasgow, and numerous scientific publications and editorials.

Dr Bunce commented: “Our customers rely on our ability to solve tough scientific questions whilst shortening timelines and ultimately improving clinical outcomes for patients. I view our role as developing drugs by proxy and guide our team to partner very closely with our customers. The combination of world class scientific excellence and technical capabilities will maximize the likelihood of success.”

Jonathan Goldman MD, Former CEO of Abzena, said:

“I am delighted to announce this appointment. Campbell deserves the newly created role of CSO, which recognizes his exceptional scientific abilities and the differentiation we bring to the customer as the only Partner Research Organization with a dedicated focus on target to GMP for biologics and ADCs. Our customers expect more than just CMO services. Our focus is making a difference for patients and I am confident that Campbell will help achieve that goal.”

About Abzena

Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and ADC drug development services in the pharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com.